1. Introduction {#s0005}
===============

*Précis:* Vitamin D supplementation does not alter the risk of coronary heart disease or stroke.

Vitamin D's role in bone metabolism is well-known. More recently it has been suggested that vitamin D supplementation may have extra-skeletal benefits including beneficial effects on cardiovascular disease (CVD) [@b0005]. This notion is supported by numerous observational and animal studies which suggest a link between vitamin D deficiency and CVD. As an example, among 18,000 healthy male participants in the Health Professionals Follow Up Study, those with 25-hydroxyvitamin D (25(OH)D) levels less than 15 ng/mL had a relative risk of 2.42 (95% CI, 1.53--3.84) compared to those with levels above 30 ng/ml for myocardial infarction (MI) after 10 years of follow-up [@b0010]. Furthermore, the interest surrounding vitamin D supplementation is supported by biologic mechanisms which suggest that vitamin D may have beneficial effects on the cardiovascular system. The liganded vitamin D receptor (VDR) has been shown to inhibit vascular smooth muscle cell proliferation, [@b0015] decrease blood pressure by a down regulation of the renin-angiotensin-aldosterone system, [@b0020] and decrease inflammation through a downregulation of interleukin-6 and interleukin-8 [@b0025]. Furthermore, the VDR has been found to be expressed in the cardiovascular system including the walls of coronary arteries and atherosclerotic coronary artery plaques [@b0030]. It has also been suggested that low levels of 25(OH)D may lead to the development of vascular calcification [@b0035]. Prior *meta*-analyses have studied the relationship between 25(OH)D and CVD [@b0040], [@b0045]. Zhang et al., found a significant inverse relationship between baseline 25(OH)D and CVD events and CVD mortality. The dose--response analysis revealed a J-shaped association between 25(OH)D and total CVD events suggesting that those with much lower 25(OH)D were at a greater risk of CVD [@b0045]. This non-linear or J-shaped association between 25(OH)D and CVD has been observed in additional studies which suggests a threshold concentration of vitamin D for which CVD risk increases [@b0050], [@b0055].

Despite observational data suggesting a potential benefit and a link between vitamin D deficiency and CVD, to date there has been few randomized controlled trials (RCTs) which test vitamin D's effect on CVD risk in a pre-specified manner. In addition, it is unknown if supplementing vitamin D in deficient patients improves CVD outcomes. Therefore, the objective of this study is to perform a systematic review and *meta*-analysis to analyze CVD outcomes in the available RCTs testing various doses of vitamin D supplementation in adults. In addition, the secondary aim of this study is to perform a *meta*-regression analysis using baseline 25(OH)D concentration as the covariate to test if the effect of vitamin D supplementation on coronary heart disease (CHD) and stroke is altered by varying plasma vitamin D concentrations in a linear fashion.

2. Methods: {#s0010}
===========

The Preferred Reporting Items for Systemic Reviews and Meta-Analysis (PRISMA) statement was followed [@b0055], [@b0060]. A search was performed to identify all prospective RCTs which tested vitamin D supplementation and analyzed various health outcomes. Relevant English language articles were found by searching Medline and Embase with search terms corresponding to "vitamin D supplementation", "cardiovascular disease", and "stroke". In addition to searching the above databases, previously published *meta*-analyses were searched as a source for RCTs. The references of all articles were also searched. RCTs testing either daily or monthly doses of vitamin D (25(OH)D) supplementation were considered for inclusion. Both 25(OH)D~2~ and 25(OH)D~3~ were considered for inclusion. RCTs which compared vitamin D supplementation to placebo were eligible for inclusion. If one of the primary endpoints of this *meta*-analysis were reported, the trial was considered for inclusion. The primary endpoints for this study included CHD events (a composite of cardiac mortality, nonfatal myocardial infarction and revascularization procedure (CABG or PCI), nonfatal MI, stroke (either hemorrhagic or ischemic), and cardiac death (sudden cardiac death, any death presumed due to a cardiovascular cause).

Two authors (MN, GK) searched all titles and abstracts. All articles were evaluated by both authors to assess if the study meets inclusion criteria. Data were independently extracted for the RCTs in a standardized manner. Regardless of the pre-specified outcome of the trial, if one of the primary endpoints of this *meta*-analysis is reported, the trial was included. The average age and number of participants at trial baseline was collected. The average follow-up time and formulation of 25(OH)D was recorded. All studies were assessed for bias using the Cochrane Handbook for Systematic Review of Interventions by two authors [@b0065]. Bias was assessed on predetermined criteria including random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting, and other (i.e. predetermined outcome of trial, financial consideration) (Supplemental Table 1).

The primary analysis was conducted with the Mantel-Haenszel method. Summary rate ratios (RR) with 95% confidence interval (CI) will be calculated using a random effects model. Examination of heterogeneity across all studies will be performed using Q statistics and I^2^. The 95% CIs will be estimated using binominal distribution. Multiple subgroup analyses were performed. A subgroup analysis was performed based on trial duration (less than 6 months versus \>6 months). Also, a subgroup analysis based on average age at trial baseline was performed (less than 60 years vs \> 60 years). Publication bias was visually assessed using funnel plots. Statistical analyses were conducted with Review Manager (RevMan) \[Computer program\]. Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. A random effects *meta*-regression was performed for the CHD events, nonfatal MI and stroke outcome using mean baseline plasma vitamin D concentration as the covariate. A *meta*-regression was not performed on the cardiac death outcome as only 2 RCTs which reported a cardiac death also reported mean baseline trial plasma vitamin D concentrations. Meta-regression linear graphs were created by plotting our moderator variable (baseline plasma vitamin D concentration) on the x-axis and the treatment effect size of vitamin D on the y-axis (the log of the rate ratio of vitamin D's treatment effect on each outcome for each RCT). Each circle on the figure represents an included RCT and the size of the circle is proportional to the weight of each study in the regression model. The darker line in the center represents the regression line and the outer lighter colored lines represent the 95% CI. The following statistical tests were utilized in the *meta*-regression: Tau^2^ which estimates the true variance among RCTs, I^2^ which represents the ratio of heterogeneity to total observed variation in the RCTs and R^2^ index which is the proportion of between study variance explained by the moderator. Also, regression coefficients were calculated and describe how vitamin D's treatment effect on each outcome will change with a unit change in the moderator variable. The *meta*-regression was performed using Comprehensive Meta-Analysis Version 3, Biostat, Englewood, NJ, 2013 [Table 1](#t0005){ref-type="table"}.Table 1Baseline Characteristics Table. This table includes the baseline characteristics of the included randomized controlled trials which includes trial design, follow up time, number of participants, mean age, dose of vitamin D, frequency of vitamin D, primary outcome and if reported baseline plasma vitamin D concentration of participants.Name, YearDesignFollow- Up (years)Number of Participants (mean age in years)Dose and CompoundPrimary OutcomeBaseline 25-hydroxyvitamin D ConcentrationBaron 2016Double-blind, placebo controlled3 or 5 years2259 patients with prior colonic adenoma (58 years)1000 IU of vitamin D dailyAdenoma occurrence24.4 ng/mLBrazier 2005Double-blind, placebo controlled1 year192 women (74.6 years)500 mg calcium carbonate and vitamin D 400 IU taken twice dailyRenal function7.2 ng/mLFord 2014Double-blind, placebo controlled2 years5292 participants with prior low trauma fracture (77.5 years)800 IU of vitamin D dailyFracturen/aGallagher 2012Double-blind placebo controlled1 year163 postmenopausal women (67 years)400, 800, 1600, 240, 3200, 4000, 4800 IU/ daily or placebo25(OH)D and PTH levels7.6 ng/mLGulseth 2017Double-blind, placebo controlled0.5 year62 men and women with type 2 diabetes and vitamin D deficiency (55.6 years)400,000 IU oral vitamin D~3~ or placebo. Those randomized to the vitamin D group received an additional 200,000 IU if 25(OH)D level was less than 100 nmol/L after 4 weeks.Insulin sensitivity15.2 ng/mlInkovaara 1983Double-blind, placebo controlled9 months87 patients (79.5 years)1000 IU/day of vitamin D or placeboBone fracturen/aJackson 2006Double-blind, placebo controlled7 years36,282 postmenopausal women (62.4 years)400 IU of vitamin D daily or placeboHip Fracturen/aJin 2016Double-blind, placebo controlled2 years413 patients with symptomatic knee osteoarthritis (63.2 years)50,000 IU of vitamin D per month vs. placeboChange in tibial cartilage volume, change in the Western Ontario and McMaster Universities Arthritis Index pain score17.48 ng/mlJorde 2016Double-blind, placebo controlled5 years511, patients with prediabetes (62 years)20,000 IU/week or placeboProgression to type 2 diabetes24.0 ng/mlKomulainen 1999Double-blind, placebo controlled5 years343 women (52.6 years)300 IU daily and 100 IU daily or placeboBone Mineral Densityn/aMatrineau 2015 (ViDiAs)Double-blind, placebo controlled1 year250 adults with asthma (48 years)3 mg of vitamin D~3~ or placeboTime to first asthma exacerbation and time to first upper respiratory tract infection19.8 ng/mLMatrineau 2015 (ViDiFlu)Double blind, placebo controlled1 year240 patients (67.1 years)2.4 mg of vitamin D every 2 months + 10 µg daily or 3 mg every 2 months vs. placeboTime to first acute respiratory infection17.2 ng/mLMiskulin 2016Double-blind, placebo controlled0.5 year276 vitamin D deficient patients with end-stage renal disease (61.1 years)50,000 IU weekly for 6 monthsChange in epotien dose16.4 ng/mLPrince 2008Double-blind, placebo controlled1 year302 vitamin D deficient women with a history of fall in the previous year (77.2 years)1000 IU per day of ergocalciferolFalls17.9 ng/mLSanders 2010Double-blind, placebo controlled3--5 years2256 women (76 years)500,000 IU yearly of vitamin DFalls and fractures19.6 ng/mLScragg 2017Double-blind, placebo controlled3.3 years5108 patients (65.9 years)200,000 IU initial dose followed by 100,000 IU q4 weeksCVD and death25.4 ng/mLTrivedi 2003Double-blind, placebo controlled5 years2686 participants (74.8 years)100,000 IU of vitamin D every 4 months over 5 yearsFracture incidence and total mortalityn/aVITAL TrialDouble-blind, placebo controlled5.3 years25,871 patients (67.1 years)2000 IU/day of vitamin D~3~ versus placeboMajor cardiovascular events and invasive cancer of any kind30.8 mg/mL (measured in 61% of baseline population)Witham 2013Double-blind, placebo controlled1 year159 participants with hypertension (77 years)100,000 IU of vitamin D every 3 months for 1 yearChange in office blood pressure18 ng/mLWitham 2010Double-blind, placebo controlled0.38 year105 patients with systolic heart failure (79.8 years)100,000 IU at baseline at and at 10 weeks vs. placebo6 min walk test8.8 ng/mLZitterman 2017Double blind, placebo controlled3 year400 patients with heart failure (55 years)4000 IU/day of vitamin D versus placeboAll-cause mortality13.2 ng/mL

3. Results {#s0015}
==========

3.1. All coronary heart disease events {#s0020}
--------------------------------------

Among trials that reported a CHD event (n = 21) there were 83,093 participants [@b0070], [@b0075], [@b0080], [@b0085], [@b0090], [@b0095], [@b0100], [@b0105], [@b0110], [@b0115], [@b0120], [@b0125], [@b0130], [@b0135], [@b0140], [@b0145], [@b0150], [@b0155], [@b0160], [@b0165], [@b0170]. The weighted mean age was 65.7 years. The mean follow-up duration was 2.6 years. Among trials that reported mean baseline 25(OH)D concentrations (n = 14) the mean concentration among all trials was 17.5 ng/ml with a range between 7.2 and 25.4 ng/ml [@b0070], [@b0075], [@b0085], [@b0100], [@b0105], [@b0115], [@b0120], [@b0125], [@b0130], [@b0135], [@b0140], [@b0155], [@b0160], [@b0165]. There was no evidence of statistical heterogeneity among all of the RCTs (Chi^2^ = 12.67, p = 0.89, I^2^ = 0%) ([Fig. 1](#f0005){ref-type="fig"}). There was no visual evidence of publication bias when viewing the funnel plot (Supplemental Fig. 3). Among participants randomized to vitamin D 2203/41,664 (5.29%) experienced a CHD event and 2194/41,429 (5.3%) in the control group experienced a CHD event (RR 0.97 \[95%CI, 0.90--1.03\]) ([Fig. 1](#f0005){ref-type="fig"}). When performing the test for subgroup differences there is no heterogeneity of treatment effect based on mean age at trial baseline (Chi^2^ = 0.66, p = 0.42, I^2^ = 0%), longer vs. shorter trial duration (Chi^2^ = 1.22, p = 0.27, I^2^ = 18%), daily vs. nondaily vitamin D supplements (Chi^2^ = 3.02, p = 0.08, I^2^ = 66.9%). However, when comparing trials which test vitamin D supplements with (RR 1.09, 95%CI 0.99--1.19) versus without calcium (RR 0.94, 95%CI 0.87--1.01) there was statistically significant heterogeneity of treatment effect (Chi^2^ = 6.86, p = 0.02, I^2^ = 82.9%) (Supplemental Figure 4). When performing the random effects *meta*-regression for CHD events, there was no relationship between plasma vitamin D concentration and the log rate ratio of vitamin D's treatment effect on CHD events \[coefficient = 0.008 (95% CI −0.05--0.06), Tau^2^ = 0.00, I^2^ = 0%, and R^2^ = 0.00\] ([Fig. 3](#f0015){ref-type="fig"}).Fig. 1Forest Plot for Coronary Heart Disease Events. This Forrest plot represents the rate ratio of coronary heart disease outcomes in those participants randomized to vitamin D supplementation and placebo. Coronary heart disease events in a composite outcome including cardiac mortality, nonfatal myocardial infarction and coronary artery revascularization procedure.

3.2. Nonfatal myocardial infarction {#s0025}
-----------------------------------

Among trials that reported a nonfatal MI (n = 13) there were 79,234 participants [@b0070], [@b0080], [@b0085], [@b0095], [@b0130], [@b0170], [@b0105], [@b0110], [@b0115], [@b0140], [@b0145], [@b0150], [@b0155]. The weighted mean age was 65.5 years. The mean follow-up duration was 3.2 years. Among trials that reported mean baseline 25(OH)D concentrations the mean among all trials was 19 ng/ml with a range between 8.8 and 25.4 ng/mL [@b0070], [@b0085], [@b0105], [@b0115], [@b0130], [@b0140], [@b0155], [@b0170]. There was no evidence of statistical heterogeneity among all of the RCTs (Chi^2^ = 5.15, p = 0.95, I^2^ = 0%) ([Fig. 2](#f0010){ref-type="fig"}). There was no visual evidence of publication bias when viewing the funnel plot (Supplemental Figure 5). Among participants randomized to vitamin D 852/39,773 (2.14%) experienced a CHD event and 862/39,461 (2.18%) in the control group experienced a nonfatal MI (RR 0.98 \[95%CI, 0.89--1.08\]) ([Fig. 2](#f0010){ref-type="fig"}). When performing the test for subgroup differences there is no heterogeneity of treatment effect based on mean age at trial baseline (Chi^2^ = 0.00, p = 0.97, I^2^ = 0%), longer vs. shorter trial duration (Chi^2^ = 0.24, p = 0.62, I^2^ = 0%), daily vs. nondaily dosages of vitamin D (Chi^2^ = 0.35, p = 0.55, I^2^ = 0%), and vitamin D supplements with versus without calcium (Chi^2^ = 1.53, p = 0.22, I^2^ = 34.8%). When performing the random effects *meta*-regression for nonfatal MI, there was no relationship between plasma vitamin D concentration and the log rate ratio of vitamin D's treatment effect on nonfatal MI \[coefficient = 0.06 (95% CI −0.12--0.02), Tau^2^ = 0.00, I^2^ = 0%, and R^2^ = 0.00\] ([Fig. 3](#f0015){ref-type="fig"}).Fig. 2Forest plot for Nonfatal Myocardial Infarction. This Forrest plot represents the rate ratio of a nonfatal myocardial infarction in those participants randomized to vitamin D supplementation or placebo.Fig. 3This figure represents the *meta*-regression analysis performed for coronary heart disease events (A), nonfatal myocardial infarction (B) and stroke (C) with mean baseline vitamin D concentration (ng/mL) as the covariate.

3.3. Cardiac death {#s0030}
------------------

Among trials that reported a cardiac death there were 75,726 participants [@b0080], [@b0090], [@b0095], [@b0165], [@b0140], [@b0145], [@b0150]. The weighted mean age of participants was 65.7 years. The mean follow-up duration was 3.8 years. Among the two trials that reported mean baseline 25(OH)D concentrations the mean among all trials was 19.3 ng/ml [@b0140], [@b0165]. There was some evidence of nonsignificant heterogeneity among all of the RCTs (Chi^2^ = 6.18, p = 0.40, I^2^ = 3%) (Supplemental [Fig. 2](#f0010){ref-type="fig"}). There was no visual evidence of publication bias when viewing the funnel plot (Supplemental Figure 6). Among participants randomized to vitamin D 589/37,899 (1.6%) experienced a cardiac death and 623/37,827 (1.7%) in the control group experienced a cardiac death (RR 0.94 \[95%CI, 0.84--1.06\]). When performing the test for subgroup differences there is no heterogeneity of treatment effect based on vitamin D supplements with versus without calcium (Chi^2^ = 1.10, p = 0.29, I^2^ = 9.1%). A *meta*-regression for the cardiac death outcome was unable to be performed due to only 2 RCTs reporting mean baseline vitamin D concentrations.

3.4. Stroke {#s0035}
-----------

Among trials that reported a stroke (n = 13) there were 79,245 participants [@b0070], [@b0080], [@b0090], [@b0095], [@b0105], [@b0110], [@b0120], [@b0130], [@b0140], [@b0145], [@b0150], [@b0155], [@b0160]. The weighted mean age was 65.6 years. The mean follow-up duration was 3.1 years. Among trials that reported mean baseline 25(OH)D concentrations the mean among all trials was 19.4 ng/ml with a range of 8.8--25.4 ng/mL [@b0070], [@b0105], [@b0120], [@b0130], [@b0140], [@b0155], [@b0160]. There was no evidence of statistical heterogeneity among all of the RCTs (Chi^2^ = 6.56, p = 0.89, I^2^ = 0%) (Supplemental Fig. 3). There was no visual evidence of publication bias when viewing the funnel plot (Supplemental Figure 7). Among participants randomized to vitamin D 825/39,735 (2.1%) experienced a stroke and 818/39,510 (2.1%) in the control group experienced a stroke (RR 1.00 \[95%CI, 0.91--1.10\]) (Supplemental Fig. 3). When performing the test for subgroup differences there is no heterogeneity of treatment effect based on mean age at trial baseline (Chi^2^ = 1.42, p = 0.23, I^2^ = 29.8%), longer vs. shorter trial duration (Chi^2^ = 1.08, p = 0.30, I^2^ = 7.4%), daily vs. nondaily dosages of vitamin D (Chi^2^ = 0.20, p = 0.66, I^2^ = 0%), and vitamin D supplements with versus without calcium (Chi^2^ = 0.00, p = 0.96, I^2^ = 0%). When performing the random effects *meta*-regression for stroke, there was no relationship between plasma vitamin D concentration and the log rate ratio of vitamin D's treatment effect on stroke \[coefficient = -0.03 (95% CI −0.23--0.17), Tau^2^ = 0.00, I^2^ = 0%, and R^2^ = 0.00\] ([Fig. 3](#f0015){ref-type="fig"}).

4. Discussion {#s0040}
=============

This *meta*-analysis found no reduction in nonfatal MI, cardiac death, CHD events and stroke in participants randomized to vitamin D supplementation of varying doses. When performing the test for subgroup differences for each outcome studied the only statistically significant finding was found when comparing trials testing vitamin D alone versus those testing vitamin D plus calcium for CHD events. However, the reduction in CHD events among participants randomized to vitamin D alone did not meet statistical significance. Furthermore, the *meta*-regression using baseline 25(OH)D concentration as the covariate did not find any relationship between 25(OH)D and vitamin D\'s effect on CHD events, nonfatal MI or stroke. There was no effect of vitamin D supplementation on CVD risk as mean baseline vitamin D levels decreased in the individual RCTs. This could have been determined based on the lack of heterogeneity in the primary analysis; however, the *meta*-regression was performed to highlight this finding.

Our results are consistent with a 2014 *meta*-analysis from Ford et al. Among twenty-one RCTs with 13,033 participants, vitamin D supplementation was not found to reduce the risk of cardiac failure (hazard ratio (HR) 0.82, 95% CI 0.58--1.15), MI (HR 0.96, 95% CI 0.83--1.10) or stroke (HR 1.07, 95% CI 0.91--1.29) [@b0175]. A more recent *meta*-analysis of RCTs by Barbarawi et al., including \> 83,000 participants found that vitamin D supplementation compared to placebo did not reduce major adverse cardiovascular events (RR 1.00, 95%CI 0.95--1.06) or all-cause mortality (RR 0.97, 95%CI 0.93--1.02) [@b0180]. This was consistent with an additional meta-analysis of RCTs which found no reduction in MI, stroke, MI mortality and total CVD among participants randomized to vitamin D [@b0185]. Furthermore, the recent publication of the VITAL trial which is included in this *meta*-analysis has assisted in our understanding of vitamin D's role in the primary prevention of CVD. This RCT tested in 2000 IU/day of vitamin D in 25,871 relatively healthy adults. After on average of 5 years of follow up there was no reduction in the primary outcome which was a composite outcome and included myocardial infarction, stroke, or death from cardiovascular causes [@b0150]. Sixty-one percent of participants had a baseline vitamin D level drawn and the mean concentration was 30.8 ng/mL. Of these participants, 12.7% had a vitamin D level below 20 ng/mL [@b0150].

Why is there no benefit with vitamin D supplementation despite observational data showing a link? The observational data is unable to establish a casual relationship between vitamin D deficiency and CVD and caution should be applied when analyzing nonrandomized studies. Many confounding variables exist in these populations which are difficult to control for and can lead to both vitamin D deficiency and CVD. These include ability for participants to perform outdoor physical activity which leads to more ultraviolet-B exposure from the sun and more vitamin D production. Obesity and increased age also result in decreased vitamin D concentrations and an increased risk of CVD. Furthermore, chronic diseases which lead to malnutrition can result and be linked to both vitamin D deficiency and CVD.

In 2015, the U.S Preventative Services Task Force (USPTF) released a recommendation statement in regard to vitamin D deficiency screening in which they found insufficient evidence to recommend screening for vitamin D deficiency in asymptomatic patients [@b0190]. In particular, no studies were identified that studied the direct benefits or harms of screening for vitamin D deficiency in adults. Also, the USPTF found no evidence to recommend vitamin D supplementation in asymptomatic patients for the prevention of skeletal or nonskeletal outcomes. These findings are consistent with an Institute of Medicine report which found insufficient evidence to recommend vitamin D supplementation for the purpose of extra-skeletal benefits and set forth the recommended dietary allowance (RDA) for vitamin D as 600 IU/day for individuals aged 1--70 years and 800 IU/day for those over the age of 71 years [@b0195].

There are limitations to performing a *meta*-analysis of this kind. There was wide variability in baseline characteristics of the included RCTs. Few trials included the endpoint of interest for this *meta*-analysis (nonfatal MI, cardiac mortality, CHD events, and stroke) in a primary pre-specified manner. Some included RCTs test a combined vitamin D and calcium supplement with fracture or bone mineral density as the primary outcome. Therefore, it is likely that these outcomes were not ascertained through rigorous adjudication methods thus predisposing them to significant bias (including recall and reporting bias). Most trials are of small size and were not designed or adequately powered to detect differences in hard CVD outcomes. Another limitation is the wide variability in dose and frequency of vitamin D tested. Given the wide range of follow up observed (0.38--7 years), a hazard ratio may have been the more appropriate measure of risk. Another limitation of the analysis is the interlaboratory variation which has been observed with vitamin D measurement [@b0200]. Measurement of vitamin D was not standardized across all RCTs. Also, the *meta*-regression tested a linear association between 25(OH)D concentrations and vitamin D's effect on CVD outcomes. Therefore, this analysis is unable to answer the question of "Does vitamin D supplementation improve CVD outcomes in deficient populations?" One way to answer this question would be to perform a RCT powered to detect differences in CVD outcomes, in deficient populations testing vitamin D supplementation versus placebo or to perform an individual participant data *meta*-analysis of RCTs. Meta-regressions are observational in nature and are therefore also subject to confounding variables and bias.

In conclusion, this *meta*-analysis found no reduction in CHD outcomes or stroke outcomes among the available RCTs testing vitamin D supplementation. Despite there being numerous observational studies and biologic mechanisms suggesting vitamin D may improve CVD, this *meta*-analysis including the available randomized data has failed to show benefit. Furthermore, a linear relationship between baseline 25(OH)D concentrations and vitamin D's effect on CVD outcomes was not observed. In line with the recent USPTF statement, clinicians should avoid overdiagnosis and overtreatment of vitamin D deficiency in adults. Vitamin D levels should only be checked and repleted in those with an absolute indication.
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The following are the Supplementary data to this article:Supplementary data 1

Supplementary data 2

**Presentation**: The following data was presented as an oral presentation at the American Heart Association's annual scientific meeting on November 12, 2018 in Chicago, IL.

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.ijcha.2020.100537>.
